PAMU
PCRX icon

Pictet Asset Management (UK)’s Pacira BioSciences PCRX Stock Holding History

Pictet Asset Management (UK)’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		$4.62M Sell
76,191
-88,150
-54% -$5.58M 0.01% 868
2021
Q1 		$11.5M Sell
164,341
-62,687
-28% -$4.48M 0.01% 626
2020
Q4 		$13.6M Sell
227,028
-12,500
-5% -$732K 0.02% 563
2020
Q3 		$14.4M Sell
239,528
-22,422
-9% -$1.3M 0.02% 480
2020
Q2 		$13.7M Sell
261,950
-24,800
-9% -$1.04M 0.02% 462
2020
Q1 		$9.62M Buy
286,750
+25,100
+10% +$1.04M 0.02% 486
2019
Q4 		$11.9M Sell
261,650
-15,300
-6% -$650K 0.02% 541
2019
Q3 		$10.5M Buy
276,950
+25,200
+10% +$1.01M 0.02% 524
2019
Q2 		$10.9M Buy
251,750
+59,750
+31% +$2.54M 0.02% 509
2019
Q1 		$7.31M Buy
192,000
+64,400
+50% +$2.51M 0.02% 608
2018
Q4 		$5.49K Buy
127,600
+35,200
+38% +$1.64M 0.01% 644
2018
Q3 		$4.54M Sell
92,400
-9,800
-10% -$424K 0.01% 762
2018
Q2 		$3.28M Buy
102,200
+5,985
+6% +$207K 0.01% 746
2018
Q1 		$3M Buy
96,215
+64,552
+204% +$2.3M 0.01% 752
2017
Q4 		$1.45M Sell
31,663
-19,703
-38% -$781K ﹤0.01% 817
2017
Q3 		$1.93M Buy
+51,366
New +$2.07M 0.01% 791

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
SCM
Spyglass Capital Management San Francisco, California $1.41B AUM 7.96% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Pictet Asset Management (UK)'s PCRX Position: Q2 2021 in Review

Pictet Asset Management (UK) reduced its Pacira BioSciences (PCRX) stake by 54% in Q2 2021, selling an estimated $5.58M and leaving 76,191 shares worth $4.62M. The position accounts for 0.01% of the portfolio, ranked #868.

Pictet Asset Management (UK) first reported a position in PCRX in Q3 2017 and has held it in 16 quarters since. The position peaked at $14.4M in Q3 2020. 262 funds tracked by Wall St. Rank hold PCRX as of Q2 2021.

  • Pictet Asset Management (UK) held 76,191 shares of Pacira BioSciences worth $4.62M as of Q2 2021.
  • Pictet Asset Management (UK) sold 88,150 Pacira BioSciences shares in Q2 2021, an estimated $5.58M.
  • Pacira BioSciences made up 0.01% of Pictet Asset Management (UK)'s portfolio in Q2 2021, its #868 holding.
  • Pictet Asset Management (UK) first reported a position in Pacira BioSciences in Q3 2017 and has held it in 16 quarters since.
  • Pictet Asset Management (UK)'s Pacira BioSciences position peaked at $14.4M in Q3 2020.
  • 262 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2021.

Based on Pictet Asset Management (UK)'s 13F filing for Q2 2021, filed 16 Aug 2021.